What Sponsors Actually Evaluate When Choosing Sites

Site selection decisions get made in rooms you're not in, by people working from a spreadsheet and a handful of internal reports. Understanding what's actually on that spreadsheet changes how you position yourself.

The three questions behind every selection decision

Stripped down, a study manager choosing between candidate sites is answering:

1. Will this site enroll on schedule?
2. Will the data hold up under monitoring and audit?
3. Will this site create work for me?

Everything else is a proxy for these. Your CV, your equipment list, your PI's publication record — they matter only insofar as they predict those three answers.

Past performance beats stated capability

Sponsors and CROs increasingly track site-level enrollment history across studies, either through their own systems or shared industry databases. If you enrolled two of a projected eight in your last indication-adjacent study, that number travels with you.

This has a practical consequence: your enrollment projections are a reputational asset. Committing to 20 and delivering 6 hurts you more than committing to 8 and delivering 9. Sites commonly over-promise during feasibility hoping to win the award, then spend the study explaining shortfalls. In most sponsor datasets, that pattern is visible.

If your history has weak spots, address them directly rather than hoping nobody looks. "We underperformed on that study because the exclusion criteria eliminated most of our diabetic population — here's how we screened our database differently for this one" is a credible answer. Silence is not.

Data quality signals they can see before awarding

Monitors and CRAs write things down, and those notes circulate. The specific signals that follow a site:

• Query resolution turnaround
• Frequency of protocol deviations, especially repeat deviations of the same type
• Time from visit to data entry
• Whether source documentation supports what's in the EDC
• Regulatory binder completeness at close-out

A site with slow enrollment but immaculate data often gets another chance. A site with fast enrollment and messy data gets audited.

Startup speed is a selection criterion now

Cycle time from site selection to first patient in has become a metric sponsors manage actively. Sites that can turn around a contract and budget in weeks rather than months have real leverage.

Concretely, this means:

• Know your own IRB timelines and be able to state them
• Have a budget template with your actual per-procedure costs, not numbers you'll research when asked
• Identify who signs your contracts and how long they typically take
• Keep CVs, licenses, financial disclosures, and training records current so essential documents aren't the bottleneck

Sites that name their startup timeline accurately and hit it build the kind of reputation that generates unsolicited invitations.

Population access, described specifically

"We have a large diabetic population" tells a sponsor nothing. "We have 1,400 patients with a T2DM diagnosis in the last 24 months, of whom roughly 380 have a documented A1c between 7.5 and 10 and are not on insulin" tells them everything. Being able to produce that second sentence — quickly, from your own records — is one of the sharper competitive advantages available to an independent site.

The relationship layer

Study managers re-select sites they enjoyed working with. That's less sentimental than it sounds: a site that answers emails within a day, flags problems early, and doesn't escalate every question to the sponsor reduces the study manager's workload measurably.

Be the site that reports a problem before the monitor finds it. That single habit does more for your selection odds than any capability statement.